The FDA assessed the protection and effectiveness of atidarsagene autotemcel depending on facts from 37 children who gained atidarsagene autotemcel in two single-arm, open up-label medical trials As well as in an expanded access program.[seven] Kids who gained treatment with atidarsagene autotemcel had been when compared to untreated small children